血友病治療市場按產品類型、通路和地區分類

Hemophilia Treatment Market, By Product Type, By Distribution Channel, and By Region

出版日期: 2025年08月11日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

血友病治療市場規模預計在 2025 年達到 171.829 億美元，預計到 2032 年將達到 264.051 億美元，2025 年至 2032 年的複合年成長率為 6.33%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	171.829億美元
效能數據	2020-2024	預測期	2025-2032
預測期間（2025-2032年）的複合年成長率：	6.33%	2032年預測	264.051億美元

血友病是一種遺傳性出血性疾病，其特徵是缺乏或缺乏稱為凝血因子（例如凝血因子 VIII）的蛋白質。大約有 13 種凝血因子，它們與血小板協同作用，幫助血液凝固。血友病分為三種：A、B 和 C。A型血友病 A是最常見的類型，由凝血因子 VIII 缺乏引起。B型血友病由凝血因子 IX 缺乏引起，血友病 C 由凝血因子 XI 缺乏引起。在大多數情況下，血友病具有家族遺傳性。血友病的主要治療方法是靜脈注射凝血因子。然而，血友病治療的高昂費用、藥物短缺以及與血漿衍生產品相關的嚴重不利事件預計將阻礙市場成長。因此，預計在預測期內，血友病發病率和盛行率的上升將推動市場成長。為了解決這個問題，主要企業正在推出產品來滿足尚未滿足的消費者需求。有關產品發布和治療的有利監管環境和指導方針是預計在預測期內推動市場成長的其他因素。

市場動態

預計預測期內，政府加大血友病治療力度的舉措將推動血友病治療市場的成長。例如，根據美國國家醫學圖書館2021年6月發表的一篇文章，世界血友病聯盟 (WFH) 已開始透過其人道主義援助計畫向中低收入國家分發凝血因子濃縮物和艾美珠單抗，以改善開發中國家有限數量的血友病患者的生活。

本次調查的主要特點

本報告對全球血友病治療市場進行了詳細分析，並以 2024 年為基準年，提供了預測期 2025-2032 的市場規模（百萬美元）和年複合成長率(CAGR)。
它還強調了各個領域的潛在商機，並說明了針對該市場的引人注目的投資提案。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，對全球血友病治療市場的主要企業進行了概述。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
全球血友病治療市場報告涉及該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球血友病治療市場的各種策略矩陣來促進決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 17,182.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.33%	2032 Value Projection:	USD 26,405.1 Mn

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor such as factor VIII. There are around 13 types of clotting factors that work with blood platelets to help in clotting of blood. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency of factor VIII. Hemophilia B occurs due to deficiency of factor IX, and Hemophilia C is caused due to factor XI deficiency.In most cases, hemophilia is passed down through families that are inherited. It is mostly passed to the male childrens. The primary treatment for hemophilia is to replace the clotting factor in the blood though intravenous infusions. However, high cost of hemophilia treatment, lack of medicines and serious adverse events associated with plasma derived derived products is expected to hinder the market growth. Consequently, rising incidence and prevalence of hemophilic disorders are expected to boost growth of the market over the forecast period. This has led to product launches by key players to fulfill the unmet needs of consumers. Favorable regulatory scenarios and guidelines for the product launches and treatment are other factors that are expected to propel growth of the market over the forecast period.

Market Dynamics

Increasing government initiatives towards hemophilia treatment is likely expected to propel the growth of hemophilia treatment market over the forecast period. For instance, according to the article published in National Library of Medicine in June 2021, World Federation of Hemophilia(WFH) started distribution of coagulation factor concentrates and emicizumab in low- and low-middle-income countries through a humanitarian aid program. This programwill hwlp to improve life of a limited number of PWH in the developing world.

Key features of the study

This report provides an in-depth analysis of the global hemophilia treatment market and provides market size (USD Mn) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global hemophilia treatment market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemophilia treatment market.

Market Segmentation

Global Hemophilia Treatment Market, By Product Type
- Plasma Derived Coagulation Factor
- Recombinant Coagulation Factor
- Antifibrinolytic Agents
- Desmopressin
Global Hemophilia Treatment Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hemophilia Treatment Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
- Takeda Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Octapharma AG
- Swedish Orphan Biovitrum AB
- Baxter International Inc.
- Biogen Inc
- Bayer AG
- CSL Behring
- Ferring B.V.
- Pfizer, Inc.
- Kedrion
- Novo Nordisk A/S
- F. Hoffmann-La Roche AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Hemophilia Treatment Market, By Product Type, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Recombinant Coagulation Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Plasma Derived Coagulation Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Antifibrinolytic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Desmopressin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)

5. Global Hemophilia Treatment Market, By Distribution Channel, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)

6. Global Hemophilia Treatment Market, By Region, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Takeda Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Swedish Orphan Biovitrum AB
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CSL Behring
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ferring B.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kedrion
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies